SYGNIS AG signs initial distribution agreement for the Asian market for the TruePrime(TM) product family with Japanese Funakoshi Co. Ltd.

SYGNIS AG / Key word(s): Agreement

2015-03-04 / 08:00


Press Release

SYGNIS AG signs initial distribution agreement for the Asian market for the TruePrime(TM) product family with Japanese Funakoshi Co. Ltd.

Distribution agreement for Japan, the second largest life science market in the world today

FUNAKOSHI is a leading Japanese life science distributor with focus on molecular biology, protein research, cell biology and diagnostics

TruePrime(TM) family for whole genome amplification without the need of synthetic random primers on stock and ready for distribution in Japan

Madrid, Spain and Heidelberg, Germany, March 04, 2015 – SYGNIS AG (Frankfurt: LIO1; ISIN: DE000A1RFM03; Prime Standard) today announced that it has signed an non-exclusive distribution agreement for SYGNIS’ TruePrime(TM) family with FUNAKOSHI Co. Ltd. for the Japanese market.

With this agreement, SYGNIS grants FUNAKOSHI the non-exclusive rights to promote, market and sell all existing as well as future products for DNA and RNA amplification from smallest amounts of samples down to single cells for applications such as next generation sequencing (NGS) in Japan. SYGNIS’ TruePrime(TM) product family is based on SYGNIS’ revolutionary novel multiple displacement amplification (MDA) technology for the amplification of various DNA or RNA species for a multitude of applications.

As a leading solution provider, FUNAKOSHI is offering a broad portfolio of quality research reagents as well as high-tech instruments in the wide fields of molecular biology, protein research, cell biology and diagnostics to customers all over Japan.

“We are very pleased about this distribution agreement for our proprietary product portfolio with FUNAKOSHI, an important gatekeeper in Japan, the second largest life science market in the world today. With its wide customer network focused on molecular biology and diagnostics, FUNAKOSHI is best positioned to leverage the benefits of our existing as well as future products to customers in molecular biology especially in the fast growing field of NGS in Japan,” Pilar de la Huerta, CEO and CFO of SYGNIS commented. “After we successfully signed distributions agreements for North America and Europe, we today were able to sign the initial agreement for the Asian markets. We are very focused and committed to building up and expanding our distribution channel program in 2015 and only just have started with our extensive marketing activities in order to make our product widely available.”

About TruePrime(TM)

TruePrime(TM) is the brand name of a revolutionary novel MDA technology and one of the key products in SYGNIS’ portfolio. TruePrime(TM) is based on the combination of the recently discovered DNA primase “TthPrimPol” and the extremely processive and high-fidelity Phi29 polymerase to amplify uniformly total genomic DNA for a multitude of applications including next generation sequencing and single cell analysis. The extraordinary strand displacement capacity of the Phi29 polymerase allows TthPrimPol to generate new primers on the displaced strands that are extended by Phi29 DNA pol, resulting in exponential isothermal DNA amplification without the need of any synthetic random primers.

The resulting benefits of this innovative approach are enormous and include complete absence of common artifacts linked to the use of oligonucleotides, a reduced amplification bias in genome coverage compared to methods using random synthetic primers, a surpassing reliability as contaminating DNA is not amplified and an exquisite reproducibility when DNA is amplified from single mammalian cells. Moreover, TruePrime(TM) shows superior sensitivity, is easy to use and works perfectly well with all commonly used NGS platforms such as Illumina and Ion Torrent.

For further information please contact:

Pilar de la Huerta
Phone: +34 91 192 36 50
MC Services AG
Raimund Gabriel
Managing Partner
Phone: +49 89 210228 30

Following the merger with X-Pol Biotech in 2012, SYGNIS specializes on the development and commercialization of products for DNA amplification and sequencing. SYGNIS AG, listed at the German Stock Exchange (Prime Standard segment, Tick: LIO1; ISIN: DE000A1RFM03), has a commercial product for whole genome DNA amplification, SensiPhi(R), licensed to an industry leading partner and is currently developing its own TruePrime(TM) product line based on its proprietary TruePrime(TM) technology for use in the fast growing field of Next Generation Sequencing. The first product for single cell DNA amplification was launched in January 2015.

### Disclaimer
This publication is intended for information only and constitutes neither an offer to sell nor an invitation to buy securities. Some statements included in this press release, relating neither to proven financial results nor other historical data, should be viewed as forward-looking, i.e. not definite. Such statements are mainly predictions of future results, trends, plans or goals. These statements should not be considered to be total guarantees since given their very nature they are subject to known and unknown risks and imponderability and can be affected by other factors as a consequence of which the actual results, plans and goals of SYGNIS AG may deviate greatly from the established conclusions or implied predictions contained in such statements. SYGNIS does not undertake to publicly update or revise these statements in the light of new information or future results or for any other reason.###

2015-03-04 Dissemination of a Corporate News, transmitted by DGAP – a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Media archive at and

329415  2015-03-04